What causes krabbe disease

What is Krabbe Disease?

Krabbe disease, also known as globoid cell leukodystrophy, is a severe and rare inherited neurological disorder that affects the nervous system. It is classified as a lysosomal storage disease, meaning that certain substances cannot be broken down properly within the body's cells. Specifically, Krabbe disease is a type of leukodystrophy, which are a group of rare inherited disorders that damage the white matter of the brain. The white matter is composed of nerve fibers (axons) that are coated with a fatty substance called myelin. Myelin acts as an insulator and helps nerve signals travel quickly and efficiently. In Krabbe disease, the production of myelin is disrupted, leading to progressive neurological deterioration.

The Genetic Basis of Krabbe Disease

Krabbe disease is an autosomal recessive disorder. This means that an individual must inherit two copies of a mutated gene, one from each parent, to develop the disease. If a person inherits only one copy of the mutated gene, they are a carrier but typically do not show symptoms. Carriers can pass the gene mutation on to their children. The gene responsible for Krabbe disease is the GALC gene, located on chromosome 14. This gene provides instructions for making the enzyme galactocerebrosidase (GALC).

The Role of the GALC Enzyme

The GALC enzyme plays a crucial role in breaking down certain fats, specifically galactolipids. Galactolipids are important components of the myelin sheath. When the GALC enzyme is deficient or absent due to mutations in the GALC gene, these galactolipids cannot be metabolized properly. This leads to the accumulation of a toxic lipid called psychosine. Psychosine is particularly harmful to oligodendrocytes, the cells responsible for producing myelin in the central nervous system. The buildup of psychosine causes these cells to die, leading to a loss of myelin (demyelination) and the formation of characteristic "globoid cells" – large, abnormal cells filled with undigested lipids. This destruction of myelin severely impairs the transmission of nerve signals throughout the brain and spinal cord, resulting in the progressive neurological symptoms seen in Krabbe disease.

Types and Symptoms

Krabbe disease can manifest in several forms, with the most common and severe being the infantile form, which typically appears within the first few months of life. Symptoms of infantile Krabbe disease often include extreme irritability, unexplained crying, muscle stiffness (hypertonia), feeding difficulties, vomiting, developmental delay, and seizures. Affected infants may also experience hypersensitivity to touch and sound, and a characteristic fever that does not respond to medication. As the disease progresses, infants may lose previously acquired skills, such as sitting or crawling, and experience vision and hearing loss. Without treatment, the infantile form is usually fatal by the age of two.

Less common forms include late-infantile, juvenile, and adult-onset Krabbe disease. These forms generally have a slower progression and may present with a wider range of symptoms, including spasticity, ataxia (problems with coordination), cognitive decline, and behavioral changes. However, even in these later-onset forms, the underlying cause remains the same: the deficiency of GALC enzyme and the subsequent accumulation of toxic lipids.

Diagnosis and Treatment

Diagnosing Krabbe disease typically involves a combination of methods. Newborn screening programs in some regions now include testing for Krabbe disease by measuring GALC enzyme activity in dried blood spots. If newborn screening is positive or if there is a clinical suspicion of Krabbe disease, further diagnostic tests are performed. These include measuring GALC enzyme activity in blood or skin cells, genetic testing to identify mutations in the GALC gene, and neuroimaging studies like MRI to assess the extent of white matter damage. A definitive diagnosis can often be confirmed by testing GALC enzyme levels.

Currently, there is no cure for Krabbe disease. Treatment focuses on managing symptoms and improving the quality of life for affected individuals. Hematopoietic stem cell transplantation (HSCT), also known as bone marrow transplant, has shown some promise, particularly when performed very early in the infantile form, before significant neurological damage has occurred. HSCT aims to provide healthy cells that can produce the deficient GALC enzyme. However, HSCT is a complex procedure with significant risks and is not always successful. Gene therapy is also an area of ongoing research, with the hope of developing more effective treatments in the future.